Preferred Label : Ivicentamab;
NCIt synonyms : DuoHexaBody-CD37; DuoHexaBody-CD37 GEN3009; Anti-CD37 Bispecific Monoclonal Antibody GEN3009;
NCIt definition : An Fc-engineered, humanized, bispecific hexamer formation-enhanced immunoglobulin
(Ig) G1 monoclonal antibody that targets two separate epitopes on the tumor-associated
antigen (TAA) CD37, with the E430G hexamerization-enhancing mutation, with potential
immunomodulating and antineoplastic activities. Upon administration, ivicentamab specifically
targets and binds to two non-overlapping CD37 epitopes, thereby inducing an assembly
of antibody hexamers through intermolecular Fc-Fc interactions at the cell surface
of CD37-overexpressing tumor cells. These hexamers recruit and activate C1, the first
component of complement, thereby triggering the complement cascade which activates
the immune system to induce complement-dependent cytotoxicity (CDC). In addition,
the binding of ivicentamab to the CD37-overexpressing tumor cells also causes antibody-dependent
cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).
CD37, a member of the tetraspanin superfamily of cell surface antigens, is expressed
at high-levels on B cells and to a lesser extent on T cells and myeloid cells. The
E430G mutation in the Fc domains enhances Fc-mediated IgG hexamerization upon cellular
target binding, and enhances CDC.;
UNII : 4O7JS64H45;
CAS number : 2364496-42-2;
Molecule name : GEN 3009; GEN-3009;
NCI Metathesaurus CUI : CL1406362;
Origin ID : C172443;
UMLS CUI : C5706675;
Currated CISMeF NLP mapping
- Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
